Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Sofosbuvir/ledipasvir raises some antiretroviral levels in HIV/HCV coinfected people

People with HIV and hepatitis C virus (HCV) co-infection who take sofosbuvir/ledipasvir (Harvoni) to treat hepatitis C along with boosted protease inhibitor antiretroviral regimens may experience changes

Published
10 March 2015
By
Liz Highleyman
Here Is Why Gilead Sciences, Inc. Is Still Doing Better Than AbbVie Inc

Based on the prescription data released by Symphony Health, the latest Bloomberg Intelligence (BI) analysis suggests that 95% of hepatitis C patients in the US are being administered with Gilead’s drugs, Harvoni and Sovaldi. On the other hand, AbbVie’s competing drug, Viekira Pak is only covering the remaining 4%.

Published
10 March 2015
From
Bidness
$10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said Managing Director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.

Published
09 March 2015
From
Bloomberg
EECA CAB positions in regards to Janssen, BMS, Gilead and ViiV policy

EECA CAB (Community Advisory Board in Eastern Europe and Central Asia) has published its positions in regards to Janssen, BMS, ViiV and Gilead policy. The positions were developed on the results of the meetings with the companies during last year.

Published
09 March 2015
From
EATG
NIH-led study to assess community-based hepatitis C treatment in Washington, D.C.

Officials from NIH and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. The trial, which will involve 600 adult D.C. residents infected with HCV alone or co-infected with HCV and HIV, also will examine the long-term effects of the treatment.

Published
09 March 2015
From
EurekAlert
Natco Pharma ties up with Gilead on hepatitis C drugs

Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.

Published
04 March 2015
From
Reuters
HCV Drugs Costly but Cure Might Not Be

Despite controversy over the cost of new hepatitis C (HCV) medications, they appear to be cheaper on a per-cure basis than earlier drugs, a researcher said here.

Published
04 March 2015
From
MedPage Today
Gilead's Harvoni gains NICE yes - but won't face funding delay

Gilead's next generation hepatitis C pill Harvoni is set to be backed by NICE - and this time NHS England won't be delaying its funding as it has done with the firm's other hep C drug Sovaldi.

Published
03 March 2015
From
PM Live
Deferring hepatitis C treatment can lead to liver cancer and death, despite cure

People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being

Published
03 March 2015
By
Liz Highleyman
Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US

The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced liver

Published
03 March 2015
By
Liz Highleyman

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.